Chemistry:Emrusolmin
From HandWiki
Emrusolmin (development code Anle138b) is an experimental drug for the treatment of neurodegenerative diseases. It is an inhibitor of protein aggregation, particularly preventing the aggregation of α-synuclein which is implicated in the development of Parkinson's disease.[1][2][3] Other proteins it inhibits the aggregation of include tau[4] which is associated with Alzheimer's disease (AD) and tauopathy, and amyloid beta[5] which is associated with AD.
It is currently in clinical trials for Parkinson's disease and multiple system atrophy.[6]
References
- ↑ "Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease". Acta Neuropathologica 125 (6): 795–813. 2013. doi:10.1007/s00401-013-1114-9. PMID 23604588.
- ↑ "Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR". Methods 214: 18–27. 2023. doi:10.1016/j.ymeth.2023.04.002. PMID 37037308.
- ↑ "The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils". Nature Communications 13 (1): 5385. 2022. doi:10.1038/s41467-022-32797-w. PMID 36104315. Bibcode: 2022NatCo..13.5385A.
- ↑ "Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies". Acta Neuropathologica 130 (5): 619–631. 2015. doi:10.1007/s00401-015-1483-3. PMID 26439832.
- ↑ "The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology". EMBO Molecular Medicine 10 (1): 32–47. 2018. doi:10.15252/emmm.201707825. PMID 29208638.
- ↑ "Emrusolmin - Modag". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800046788.
 |  |
